Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02564588 · ClinicalTrials.gov registry record · Phase 2

Dasotraline Binge Eating Disorder Study

A Phase 2 study of Binge-Eating Disorder, sponsored by Sumitomo Pharma America.

Completed
Registry status
Phase 2
Development phase
319
Enrollment target
20
Study locations

NCT02564588 is a Phase 2 study of Binge-Eating Disorder that has completed, run by Sumitomo Pharma America. The registered enrollment target is 319 participants, below the 1,135-participant average among 37 other Binge-Eating Disorder trials with a reported enrollment target (72% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02564588, a Phase 2 study of Binge-Eating Disorder, has completed, sponsored by Sumitomo Pharma America.

COMPLETED
Registry status
Phase 2
Development phase
319 participants
Enrollment target
20
Study locations

Study Summary

Evaluate the efficacy of flexibly-dosed dasotraline compared with placebo in adults with moderate to severe Binge Eating Disorder (BED)

Conditions Studied

Binge-Eating Disorder

Interventions

  • DRUG Placebo
  • DRUG Dasotraline

Study Locations (20)

California

  • Southern California Research - Beverly Hills
  • Southwestern Research, Inc. - Beverly Hills
  • Pharmacology Research Institute - Encino
  • Collaborative NeuroScience Network Inc. - Garden Grove
  • Pharmacology Research Institute - Newport Beach
  • PCSD- Feighner Research - San Diego
  • Research Across America - Santa Ana

Florida

  • Clinical Neuroscience Solutions, Inc. - Jacksonville
  • Segal Institute for Clinical Research - North Miami
  • Clinical Neuroscience Solutions, Inc. - Orlando
  • Miami Research Associates - South Miami

Georgia

  • Institute of Advanced Medical Research - Alpharetta
  • Neurotrials Research, INC. - Atlanta

Massachusetts

  • McLean Hospital - Belmont
  • Adams Clinical Trials, LLC - Watertown

Colorado

  • Lytle and Weiss, PLLC - Denver

Illinois

  • Capstone Clinical Research - Libertyville

Indiana

  • Goldpoint Clinical Research, Inc. - Indianapolis

Kansas

  • Cypress Medical Research Center, LLC - Wichita

Trial Details

FieldValue
Enrollment Target 319 participants
Start Date 2015-10
Est. Completion 2016-10
Phase Phase 2

Sponsor

Sumitomo Pharma America

168 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02564588

The ClinicalTrials.gov registry entry for NCT02564588 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 319 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,135-participant average among 37 other Binge-Eating Disorder trials with a reported enrollment target (72% lower). The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Binge-Eating Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02564588 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT02564588 about?

NCT02564588 is a clinical study titled "Dasotraline Binge Eating Disorder Study". Evaluate the efficacy of flexibly-dosed dasotraline compared with placebo in adults with moderate to severe Binge Eating Disorder (BED)

What is the current status of trial NCT02564588?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 319 participants. The study started on 2015-10. Estimated completion is 2016-10.

What conditions does trial NCT02564588 study?

This clinical trial studies the following conditions: Binge-Eating Disorder.

What interventions are being tested in trial NCT02564588?

The interventions under investigation include: Placebo (DRUG), Dasotraline (DRUG).

Who is sponsoring clinical trial NCT02564588?

This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02564588 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Binge-Eating Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Binge-Eating Disorder

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.